Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

Imagem de Miniatura
Arquivos
art_RIECHELMANN_Antiangiogenic_therapy_for_refractory_colorectal_cancer_current_options_2017.PDF (714.56 KB)
Citações na Scopus
34
Tipo de produção
article
Data de publicação
2017
Editora
SAGE PUBLICATIONS LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
GROTHEY, Axel
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, v.9, n.2, p.106-126, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Even though significant improvements in the treatment of colorectal cancer (CRC) have been made in recent years, survival rates for metastatic colorectal cancer (mCRC) are poor. Effective treatment options for metastatic colorectal cancer remain limited, and new therapeutic strategies are desperately needed. Several tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) that target angiogenesis, a critical process for facilitating tumor cell growth, invasion, and metastasis, are either approved or in clinical development for the treatment of mCRC. Many of these agents have shown efficacy in mCRC, both as single agents and in combination with standard chemotherapy regimens. However, there is a need for predictive markers of response to identify those patients most likely to benefit from antiangiogenic therapy, and, to date, no markers of this type have been validated in patients. Additionally, because antiangiogenic agents typically cause cytostatic as opposed to cytotoxic antitumor effects, it is important to determine the best strategies for evaluating therapeutic response in mCRC to ensure maximum clinical benefit. In this review, we summarize the efficacy and tolerability of approved and investigational antiangiogenic agents for the treatment of mCRC. We also discuss potential markers of response to antiangiogenic agents and how these markers, along with appropriate endpoint selection, can improve clinical trial design.
Palavras-chave
antiangiogenic, biomarker, colorectal cancer, monoclonal antibody, tyrosine kinase inhibitor
URI
https://observatorio.fm.usp.br/handle/OPI/20209
Referências
  1. Albert DH, 2006, MOL CANCER THER, V5, P995, DOI 10.1158/1535-7163.MCT-05-0410
  2. American Cancer Society, 2015, CANC FACTS FIG 2015
  3. Bayer Health Care Pharmaceuticals, 2015, NEX SOR TABL OR PACK
  4. Bayer Inc, 2015, STIV REG TABL OR PAC
  5. Bendell JC, 2015, ASCO M S, V33, P704
  6. Bendell JC, 2013, CLIN COLORECTAL CANC, V12, P239, DOI 10.1016/j.clcc.2013.09.001
  7. Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
  8. Bhide RS, 2006, J MED CHEM, V49, P2143, DOI 10.1021/jm051106d
  9. Boehringer Ingelheim Pharmaceuticals, 2014, OFEV NINT CAPS OR US
  10. Bouche O, 2011, ANTICANCER RES, V31, P2271
  11. Bruhn MA, 2014, INT J CANCER, V135, P731, DOI 10.1002/ijc.28698
  12. Buyse M, 2007, J CLIN ONCOL, V25, P5218, DOI 10.1200/JCO.2007.11.8836
  13. Cao YF, 2009, INT J COLORECTAL DIS, V24, P677, DOI 10.1007/s00384-009-0655-9
  14. Capdevila J, 2014, CRIT REV ONCOL HEMAT, V92, P83, DOI 10.1016/j.critrevonc.2014.05.004
  15. Carrato A, 2013, J CLIN ONCOL, V31, P1341, DOI 10.1200/JCO.2012.45.1930
  16. Cascinu S, 2002, BRIT J CANCER, V86, P744, DOI 10.1038/sj/bjc/6600155
  17. Cassidy J, 2011, BRIT J CANCER, V105, P58, DOI 10.1038/bjc.2011.201
  18. Chen C, 2014, J BUON, V19, P917
  19. Choueiri TK, 2008, CURR OPIN INVEST DR, V9, P658
  20. Chun YS, 2009, JAMA-J AM MED ASSOC, V302, P2338, DOI 10.1001/jama.2009.1755
  21. Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113
  22. Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004
  23. Cunningham D, 2013, BRIT J CANCER, V108, P493, DOI 10.1038/bjc.2012.545
  24. Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2
  25. Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
  26. Davies MM, 2000, BRIT J CANCER, V82, P1004
  27. de Geus-Oei LF, 2009, J NUCL MED, V50, p43S, DOI 10.2967/jnumed.108.057224
  28. de Haas S, 2014, ANGIOGENESIS, V17, P909, DOI 10.1007/s10456-014-9438-1
  29. Del Prete M, 2015, ONCOTARGET, V6, P33982, DOI 10.18632/oncotarget.5053
  30. Del Prete M, 2014, J CLIN ONCOL, V32
  31. Diaz-Rubio E, 2012, ONCOLOGIST, V17, P15, DOI 10.1634/theoncologist.2011-0249
  32. Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
  33. Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
  34. Eli Lilly and Company, 2015, CYR RAM INJ INTR US
  35. European Medicines Agency, 2015, OF CAPS SUMM PROD CH
  36. European Medicines Agency, 2015, VARG CAPS SUMM PROD
  37. Fuchs CS, 2008, J CLIN ONCOL, V26, P689, DOI 10.1200/JCO.2007.15.5390
  38. Fuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
  39. Gaur S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-21
  40. Genentech Inc, 2014, AVASTIN BEV SOL INTR
  41. Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
  42. Gill S, 2011, CURR ONCOL, V18, pS5
  43. Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
  44. Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
  45. Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
  46. Hansen TF, 2015, BRIT J CANCER, V112, P624, DOI 10.1038/bjc.2014.652
  47. Hansen TF, 2013, BRIT J CANCER, V109, P1243, DOI 10.1038/bjc.2013.448
  48. Hansen TF, 2014, MOL CANCER THER, V13, P2238, DOI 10.1158/1535-7163.MCT-14-0131
  49. Hansen TF, 2012, INT J COLORECTAL DIS, V27, P715, DOI 10.1007/s00384-011-1382-6
  50. Hayashi H, 2014, ONCOTARGET, V5, P2588
  51. Hecht JR, 2011, J CLIN ONCOL, V29, P1997, DOI 10.1200/JCO.2010.29.4496
  52. Hegde PS, 2013, CLIN CANCER RES, V19, P929, DOI 10.1158/1078-0432.CCR-12-2535
  53. Hegewisch-Becker S, 2015, LANCET ONCOL, V16, P1355, DOI 10.1016/S1470-2045(15)00042-X
  54. Hendlisz A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138341
  55. Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307
  56. Hochster HS, 2008, J CLIN ONCOL, V26, P3523, DOI 10.1200/JCO.2007.15.4138
  57. Hoff PM, 2012, J CLIN ONCOL, V30, P3596, DOI 10.1200/JCO.2012.42.6031
  58. Hu-Lowe DD, 2008, CLIN CANCER RES, V14, P7272, DOI 10.1158/1078-0432.CCR-08-0652
  59. Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
  60. Hurwitz HI, 2014, CLIN ONCOL-UK, V26, P323, DOI 10.1016/j.clon.2014.03.001
  61. Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
  62. Ince WL, 2005, J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174
  63. Infante JR, 2013, CANCER-AM CANCER SOC, V119, P2555, DOI 10.1002/cncr.28112
  64. Innocenti F., 2015, J CLIN ONCOL, V33
  65. Jackson A, 2007, CLIN CANCER RES, V13, P3449, DOI 10.1158/1078-0432.CCR-07-0238
  66. Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987
  67. Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
  68. Joseph M., 2015, J CLIN ONCOL, V33
  69. Jurgensmeier JM, 2013, BRIT J CANCER, V108, P1316, DOI 10.1038/bjc.2013.79
  70. Kasi PM, 2015, EXPERT REV GASTROENT, V9, P273, DOI 10.1586/17474124.2015.1001743
  71. Khan K., 2015, CURR DRUG TARGETS
  72. Khoja L, 2014, J CLIN GASTROENTEROL, V48, P430, DOI 10.1097/MCG.0b013e3182a8804c
  73. Koutras AK, 2012, PHARMACOGENOMICS J, V12, P468, DOI 10.1038/tpj.2011.37
  74. Kubicka S, 2013, ANN ONCOL, V24, P2342, DOI 10.1093/annonc/mdt231
  75. Lee CK, 2015, AM J CANCER RES, V5, P72
  76. Lee JC, 2000, EUR J CANCER, V36, P748, DOI 10.1016/S0959-8049(00)00003-4
  77. Lee SH, 2005, CLIN CANCER RES, V11, P3633, DOI 10.1158/1078-0432.CCR-04-2129
  78. Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969
  79. Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
  80. Li SP, 2012, J MAGN RESON IMAGING, V35, P745, DOI 10.1002/jmri.22838
  81. Lim Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145004
  82. Liu YM, 2013, CANCER MED-US, V2, P234, DOI 10.1002/cam4.71
  83. LoRusso PM, 2014, INVEST NEW DRUG, V32, P303, DOI 10.1007/s10637-013-9998-8
  84. Lv C, 2013, CANCER BIOTHER RADIO, V28, P501, DOI 10.1089/cbr.2012.1458
  85. Maeda K, 2000, INT J MOL MED, V5, P373
  86. Maisonobe JA, 2013, EUR J NUCL MED MOL I, V40, P166, DOI 10.1007/s00259-012-2274-x
  87. Martinetti A, 2014, CANCERS, V6, P1753, DOI 10.3390/cancers6031753
  88. Masi G, 2015, ANN ONCOL, V26, P724, DOI 10.1093/annonc/mdv012
  89. Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092
  90. Mross K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-510
  91. Nagengast WB, 2011, CANCER RES, V71, P143, DOI 10.1158/0008-5472.CAN-10-1088
  92. Nakamura K, 2006, CANCER RES, V66, P9134, DOI 10.1158/0008-5472.CAN-05-4290
  93. Nakayama Y, 2002, ANTICANCER RES, V22, P2437
  94. National Comprehensive Cancer Network, 2015, NCCN CLIN PRACT GUID
  95. O'Neil BH, 2014, CLIN COLORECTAL CANC, V13, P156, DOI 10.1016/j.clcc.2014.04.001
  96. Padhani Anwar R, 2009, Neoplasia, V11, P102
  97. Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
  98. Passardi A, 2015, ANN ONCOL, V26, P1201, DOI 10.1093/annonc/mdv130
  99. Pentheroudakis G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-111
  100. Pericay C, 2012, ANN ONCOL, V23, P16
  101. Petrelli F, 2013, CLIN COLORECTAL CANC, V12, P145, DOI 10.1016/j.clcc.2013.04.006
  102. Pfizer Inc, 2011, SUT SUN MAL CAPS OR
  103. Pfizer Inc, 2012, INL AX TABL OR ADM P
  104. Price TJ, 2011, J CLIN ONCOL, V29, P2675, DOI 10.1200/JCO.2010.34.5520
  105. Roskoski R, 2007, BIOCHEM BIOPH RES CO, V356, P323, DOI 10.1016/j.bbre.2007.02.156
  106. Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
  107. Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
  108. Samalin E, 2014, BRIT J CANCER, V110, P1148, DOI 10.1038/bjc.2013.813
  109. Samalin E, 2016, J CLIN ONCOL, V34
  110. Sanofi-Aventis, 2012, ZALTR ZIV AFL INJ IN
  111. Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355
  112. Semrad T., 2016, J CLIN ONCOL, V34
  113. Shi Q, 2015, J CLIN ONCOL, V33, P22, DOI 10.1200/JCO.2014.56.5887
  114. Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
  115. Siu LL, 2013, J CLIN ONCOL, V31, P2477, DOI 10.1200/JCO.2012.46.0543
  116. Stein A, 2016, CLIN COLORECTAL CANC, V15, pE29, DOI 10.1016/j.clcc.2015.12.005
  117. Tabernero J, 2015, LANCET ONCOL, V16, P937, DOI 10.1016/S1470-2045(15)00138-2
  118. Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
  119. Tabernero J, 2013, CLIN CANCER RES, V19, P2541, DOI 10.1158/1078-0432.CCR-13-0107
  120. Tang PA, 2007, J CLIN ONCOL, V25, P4562, DOI 10.1200/JCO.2006.08.1935
  121. Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723
  122. Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
  123. Tuncbilek N, 2004, ABDOM IMAGING, V29, P166, DOI 10.1007/s00261-003-0090-2
  124. Van Cutsem E, 2015, ANN ONCOL, V26, P2085, DOI 10.1093/annonc/mdv286
  125. Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
  126. Van Cutsem E, 2009, ANN ONCOL, V20, P1842, DOI 10.1093/annonc/mdp233
  127. Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
  128. Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
  129. Van Cutsem E, 2011, J CLIN ONCOL, V29, P2004, DOI [10.1200/JCO.2010.32.2701, 10.1200/JCO.2010.29.5436]
  130. Van der Veldt AAM, 2012, CANCER CELL, V21, P82, DOI 10.1016/j.ccr.2011.11.023
  131. Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
  132. Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
  133. Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
  134. Wilson MK, 2015, LANCET ONCOL, V16, pE32, DOI 10.1016/S1470-2045(14)70375-4
  135. Wolpin BM, 2013, ONCOLOGIST, V18, P377, DOI 10.1634/theoncologist.2012-0378
  136. Wood JM, 2000, CANCER RES, V60, P2178
  137. Young PE, 2014, J CANCER, V5, P262, DOI 10.7150/jca.7988

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03